Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAspirus Arise Adstiladrin Coverage Update | OpenPa…
    Ask Trek AI about this page
    CurrentAspirus ArisePolicy N/A

    Adstiladrin (nadofaragene firadenovec) for NMIBC — Oncology (Intravesical) - Adstiladrin UM Medical Policy

    Customize your policy alerts

    Sign up for all Aspirus Arise policy alerts

    Know when Aspirus Arise releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers prior authorization, coverage criteria, dosing, and approval durations for Adstiladrin intravesical therapy in adults with high-risk BCG-unresponsive non‑muscle invasive bladder cancer; applies to Aspirus Medicare plans and requires specialist prescribing or consultation.

    Policy Summary
    PayerAspirus Arise
    PolicyAdstiladrin (nadofaragene firadenovec) for NMIBC — Oncology (Intravesical) - Adstiladrin UM Medical Policy
    Policy CodePolicy N/A
    Change TypeCriteria and approval-duration revisions (material)
    Effective DateNov 15, 2023
    Last ReviewApr 30, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and document age, diagnosis (high-risk BCG-unresponsive NMIBC), histology status, and that the medication is prescribed by or in consultation with a urologist or oncologist.
    SourceLink
    POLICY UPDATE CHANGES

    Policy name changed from 'Oncology (Other) - Adstiladrin UM Medical Policy' to 'Oncology (Intravesical) - Adstiladrin UM Medical Policy'.

    Approval duration language modified: removed 1 year approval and changed to 'approve for the duration noted'; initial therapy approval defined as 4 months (to allow 2 doses) and continuation approvals of 3 months for ongoing therapy.

    Criteria for initial therapy refined to require patient be 6gt;=18, have high-risk BCG-unresponsive disease, have CIS or high-grade Ta/T1 without CIS, and prescribing by or in consultation with a urologist or oncologist.

    Added option for approval of patients currently receiving Adstiladrin for 3 months if in remission or cytology-positive with imaging/cystoscopy negative disease and prescribed by or in consultation with urology/oncology.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    75 mLapproved intravesical dose per administration
    every 3 monthsdosing interval
    4 monthsinitial approval duration
    3 monthscontinuing approval duration
    NCCN 1.2025guideline citation

    Coverage Criteria for Adstiladrin (nadofaragene firadenovec)

    FDA‑Approved Indication Criteria

    Approve when ONE of the following (A or B) is met

    A or B: A) Initial Therapy OR B) Currently receiving Adstiladrin
    A) Initial Therapy: Approve for 4 months to allow 2 doses to be given (3 months apart) if ALL of the following are met
    A.i Age: Patient is ≥ 18 years of age
    A.ii Disease status: Patient has high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive disease
    A.iii Tumor type: Patient meets ONE of the following: a) carcinoma in situ (CIS) OR b) high-grade papillary Ta/T1 tumors without CIS
    A.iv Prescriber: Medication is prescribed by or in consultation with a urologist or an oncologist
    B) Currently receiving Adstiladrin: Approve for 3 months to allow a single dose to be administered 3 months after the most recent dose if BOTH of the following are met
    B.i Response status: Patient meets ONE of the following: a) in remission on cytology and cystoscopic examination OR b) cytology-positive, imaging- and cystoscopy-negative, recurrent or persistent disease
    B.ii Prescriber: Medication is prescribed by or in consultation with a urologist or an oncologist

    Coverage is not recommended for requests that do not meet the Recommended Authorization Criteria. The policy’s authorization criteria define the clinical scenarios in which Adstiladrin (nadofaragene firadenovec) intravesical therapy may be approved; situations outside those listed criteria are not recommended for approval.

    This policy’s non‑coverage statement applies to any circumstance not explicitly included in the Recommended Authorization Criteria. Criteria will be updated as new published data become available; until then, coverage is limited to the listed indications and requirements.

    Product Coding and Key Attributes

    Drug/Productmixed
    nadofaragene firadenovec-vncgAdstiladrin (intravesical suspension)
    Age
    Age eligibility>= 18 years
    Approval window for initial therapyApprove for 4 months to allow 2 doses (3 months apart)
    Approval window for patients currently receiving therapyApprove for 3 months to allow a single dose 3 months after the most recent dose

    Prior Authorization, Documentation, and Prescribing Requirements

    Prior Authorization

    Prior authorization recommended; defined approval windows

    Prior authorization is recommended for Adstiladrin. Initial approvals should be issued for 4 months to allow two doses (given 3 months apart). Approvals for patients already receiving Adstiladrin should be issued for 3 months. All approvals are provided for the duration noted and require that the medication be prescribed by or in consultation with a physician who specializes in the condition (urologist or oncologist).

    • Initial therapy: approve for 4 months to allow 2 doses (3 months apart).
    • Currently receiving: approve for 3 months to allow a single dose 3 months after the most recent dose.
    • All approvals provided for the duration noted; specialist prescribing/consultation required.
    Step Therapy

    No mandated step therapy; specialist involvement required

    No specific step therapy sequence is mandated by this policy. Prescribing or continuation of Adstiladrin must be by or in consultation with a urologist or an oncologist.

    Background and Clinical Context

    Adstiladrin is a gene‑therapy product used intravesically for high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer. Prior authorization is recommended and approval is limited to the specific clinical scenarios described in the Recommended Authorization Criteria; requests falling outside those scenarios are not recommended for approval.

    Key Definitions

    BCG‑unresponsive NMIBC definition
    DefinitionHigh-risk non‑muscle invasive bladder cancer (BCG‑unresponsive NMIBC): disease that is failing or unresponsive to Bacillus Calmette‑Guérin (BCG) therapy and includes carcinoma in situ (CIS) with or without papillary tumors and high‑grade Ta/T1 tumors without CIS
    IncludesCarcinoma in situ (CIS) with or without papillary tumors
    Also includesHigh‑grade papillary Ta/T1 tumors without CIS
    Context of indicationAdstiladrin is indicated for BCG‑unresponsive high‑risk NMIBC in adults

    Line of Therapy

    first-line

    Recommended use setting:

    Use setting: Recommended as initial treatment for BCG-unresponsive high-risk NMIBC (CIS \u00b1 papillary) or for cytology-positive, imaging/cystoscopy-negative recurrent or persistent disease; supported by NCCN (v1.2025) guidance

    Covered Regimens and Dosing

    RegimenDose & AdministrationIntervalCoverage Status
    Adstiladrin intravesical regimen
    75 mL of Adstiladrin instilled into the bladder via urinary catheter
    Once every 3 months
    Covered with criteria
    Policy Summary
    PayerAspirus Arise
    PolicyAdstiladrin (nadofaragene firadenovec) for NMIBC — Oncology (Intravesical) - Adstiladrin UM Medical Policy
    Policy CodePolicy N/A
    Change TypeCriteria and approval-duration revisions (material)
    Effective DateNov 15, 2023
    Last ReviewApr 30, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and document age, diagnosis (high-risk BCG-unresponsive NMIBC), histology status, and that the medication is prescribed by or in consultation with a urologist or oncologist.
    SourceLink
    On This Page
    Coverage Criteria for Adstiladrin (nadofaragene firadenovec)Product Coding and Key AttributesPrior Authorization, Documentation, and Prescribing RequirementsBackground and Clinical ContextKey DefinitionsLine of TherapyCovered Regimens and Dosing
    • Policy does not require prior medication trials or a step sequence before Adstiladrin.
    • Specialist (urology or oncology) prescribing/consultation is required.
    Documentation Required

    Documentation required to support prior authorization

    Prior authorization requires documentation that the patient meets age and diagnostic criteria and that the medication is prescribed by or in consultation with an appropriate specialist.

    • Proof patient is ≥ 18 years of age.
    • Documentation the patient has high‑risk, BCG‑unresponsive disease and meets tumor-type criteria (CIS, or high‑grade Ta/T1 without CIS).
    • If requesting continuation, documentation of response status (remission on cytology and cystoscopy OR cytology‑positive with imaging/cystoscopy negative recurrent or persistent disease).
    • Evidence that medication is prescribed by or in consultation with a urologist or an oncologist.
    Denial Risk

    Requests outside criteria are not recommended for approval

    Requests that do not meet the Recommended Authorization Criteria are not recommended for approval.

    • Coverage is not recommended for circumstances outside the listed Recommended Authorization Criteria.